{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:31:40Z","timestamp":1793367100270,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018968","name":"Jamia Millia Islamia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jgar.2025.08.003","type":"journal-article","created":{"date-parts":[[2025,8,10]],"date-time":"2025-08-10T14:19:30Z","timestamp":1754835570000},"page":"442-448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Retrospective analysis of antimicrobial resistance among Escherichia coli causing community-acquired urinary tract infections in the United States from 2010 to 2022"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5961-6238","authenticated-orcid":false,"given":"Stephen James Ryan","family":"Arends","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin K.","family":"McCreary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Helgeson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2579-1657","authenticated-orcid":false,"given":"Gina","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4017-7182","authenticated-orcid":false,"given":"Shilpa","family":"Patkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2025.08.003_bib0001","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrmicro3432","article-title":"Urinary tract infections: epidemiology, mechanisms of infection and treatment options","volume":"13","author":"Flores-Mireles","year":"2015","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jgar.2025.08.003_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.idc.2013.09.003","article-title":"Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden","volume":"28","author":"Foxman","year":"2014","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.jgar.2025.08.003_bib0003","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.08.003_bib0004","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.3390\/biomedicines11112937","article-title":"Extended-spectrum beta-lactamases (ESBL): challenges and opportunities","volume":"11","author":"Husna","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.jgar.2025.08.003_bib0005","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(23)02196-7","article-title":"Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials","volume":"403","author":"Wagenlehner","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2025.08.003_bib0006","doi-asserted-by":"crossref","first-page":"e00314","DOI":"10.1128\/mSphere.00314-16","article-title":"Escherichia coli sequence type 131 H30 is the main driver of emerging extended-spectrum-beta-lactamase-producing E. coli at a tertiary care center","volume":"1","author":"Johnson","year":"2016","journal-title":"mSphere"},{"key":"10.1016\/j.jgar.2025.08.003_bib0007","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00377-13","article-title":"The epidemic of extended-spectrum-beta-lactamase-producing Escherichia coli ST131 is driven by a single highly pathogenic subclone, H30-rx","volume":"4","author":"Price","year":"2013","journal-title":"MBio"},{"key":"10.1016\/j.jgar.2025.08.003_bib0008","doi-asserted-by":"crossref","first-page":"ofw281","DOI":"10.1093\/ofid\/ofw281","article-title":"The increase in hospitalizations for urinary tract infections and the associated costs in the United States, 1998-2011","volume":"4","author":"Simmering","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2025.08.003_bib0009","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.annemergmed.2020.08.022","article-title":"Emergence of extended-spectrum beta-lactamase urinary tract infections among hospitalized emergency department patients in the United States","volume":"77","author":"Talan","year":"2021","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.jgar.2025.08.003_bib0010","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/jhm.2157","article-title":"Impact of extended-spectrum beta-lactamase-producing organisms on clinical and economic outcomes in patients with urinary tract infection","volume":"9","author":"MacVane","year":"2014","journal-title":"J Hosp Med"},{"key":"10.1016\/j.jgar.2025.08.003_bib0011","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1093\/ofid\/ofz058","article-title":"SENTRY program participating sites (1997-2016)","volume":"6","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2025.08.003_bib0012","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/ofid\/ofy346","article-title":"The importance of antimicrobial resistance monitoring worldwide and the origins of SENTRY Antimicrobial Surveillance Program","volume":"6","author":"Fuhrmeister","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2025.08.003_bib0013","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1093\/ofid\/ofy345","article-title":"Antimicrobial resistance surveillance and new drug development","volume":"6","author":"Sader","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2025.08.003_bib0014","unstructured":"Centers for Disease Control and Prevention (CDC). Identifying healthcare-associated infections (HAI) for NHSN surveillance. 2024. Available from: https:\/\/www.cdc.gov\/nhsn\/PDFs\/pscManual\/2PSC_IdentifyingHAIs_NHSNcurrent.pdf. Accessed: January 31, 2024."},{"key":"10.1016\/j.jgar.2025.08.003_bib0015","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","year":"2018"},{"key":"10.1016\/j.jgar.2025.08.003_bib0016","series-title":"Performance standards for antimicrobial susceptibility testing: 33rd informational supplement","year":"2023"},{"key":"10.1016\/j.jgar.2025.08.003_bib0017","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. 2023. Available from: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_13.0_Breakpoint_Tables.pdf. Accessed: January 31, 2024."},{"key":"10.1016\/j.jgar.2025.08.003_bib0018","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2025.08.003_bib0019","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/cid\/ciab560","article-title":"Antimicrobial resistance trends in urine Escherichia coli isolates from adult and adolescent females in the United States from 2011 to 2019: rising ESBL strains and impact on patient management","volume":"73","author":"Kaye","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.08.003_bib0020","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00430-022-00749-2","article-title":"Resistance to fosfomycin is increasing and is significantly associated with extended-spectrum beta-lactamase-production in urinary isolates of Escherichia coli","volume":"211","author":"Rios","year":"2022","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.jgar.2025.08.003_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106574","article-title":"SUsceptibility and resistance to Fosfomycin and other antimicrobial agents among pathogens causing lower urinary tract infections: findings of the SURF study","volume":"59","author":"Tutone","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2025.08.003_bib0022","doi-asserted-by":"crossref","first-page":"dlaf012","DOI":"10.1093\/jacamr\/dlaf012","article-title":"In vitro antimicrobial activity of nitroxoline against uropathogens isolated from China","volume":"7","author":"Yi","year":"2025","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.jgar.2025.08.003_bib0023","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01525-22","article-title":"Antimicrobial activity of isolates causing urinary tract infections in medical centers worldwide (2019-2020)","volume":"67","author":"Arends","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.08.003_bib0024","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/jac\/dkg028","article-title":"An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project","volume":"51","author":"Kahlmeter","year":"2003","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525001869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525001869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T07:15:41Z","timestamp":1777101341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716525001869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":24,"alternative-id":["S2213716525001869"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2025.08.003","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retrospective analysis of antimicrobial resistance among Escherichia coli causing community-acquired urinary tract infections in the United States from 2010 to 2022","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2025.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}